Roche Annual General Meeting 2024
12 Março 2024 - 9:30AM
UK Regulatory
Roche Annual General Meeting 2024
- All proposals of the Board
of Directors approved
- Severin Schwan re-elected
as Chairman of the Board of Directors; all other Board members
standing for election confirmed
- 37th consecutive dividend
increase to CHF 9.60 per share
Basel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today
announced that its shareholders had approved all proposals of the
Board of Directors at its Annual General Meeting. The 635
shareholders in attendance, who represented 77.02% of the total
106,691,000 shares, approved the Annual Financial Statements and
Consolidated Financial Statements for 2023, the Remuneration Report
and the Sustainability Report.
Severin Schwan was re-elected as Chairman of the Board of
Directors by 97.75% of the votes. Addressing the shareholders in a
speech, he said:
"Both the Pharmaceuticals and Diagnostics Divisions delivered
strong results in 2023. In particular, I would like to emphasise
the strong development of our base business. As a result, we grew
on a currency-adjusted basis - despite the significant decline in
sales of COVID-19 products. We have a broad product pipeline with
82 drug candidates, ten of which are already in the final phase of
clinical development. We have a strong presence in the key areas of
oncology, immunology and neurology. We are also expanding into new
areas, including obesity. In our Diagnostics Division, we will
launch more new products in 2024 than ever before. We are well
positioned for the future."
In addition, shareholders approved an increase in the dividend
for the past financial year to 9.60 Swiss francs (gross) per share
and non-voting equity security. This is the 37th dividend increase
in succession. Shareholders also authorised the discharge of the
members of the Board of Directors and the Corporate Executive
Committee.
The shareholders approved the total bonuses of the Corporate
Executive Committee for the 2023 financial year by 95.75% of votes,
and the bonus for the resigned Chairman of the Board of Directors
for the 2023 financial year by 95.73% of votes. They also approved
a maximum total future remuneration by 95.61% of votes for the
Board of Directors and by 97.87% of votes for the Corporate
Executive Committee until the 2025 Annual General
Meeting.
In addition to Severin Schwan, all other members of the Board of
Directors who were up for election were re-elected to the Board of
Directors for a one-year term:
- André Hoffmann
- Dr Jörg Duschmalé
- Dr Patrick Frost
- Anita Hauser
- Professor Dr Akiko Iwasaki
- Professor Dr Richard P. Lifton
- Dr Jemilah Mahmood
- Dr Mark Schneider
- Dr Claudia Süssmuth Dyckerhoff
The following Board members standing for election were
re-elected to the Remuneration Committee for a one-year term:
- André Hoffmann
- Dr Jörg Duschmalé
- Anita Hauser
- Professor Dr Richard P. Lifton
The Annual General Meeting appointed KPMG AG as statutory
auditors for the 2024 financial year and Testaris AG as independent
proxy until the conclusion of the 2025 Annual General Meeting.
The address by Chairman of the Board of Directors Severin Schwan
to shareholders will be available at
https://www.roche.com/about/governance/annual-general-meetings.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person, we partner with many stakeholders
and combine our strengths in Diagnostics and Pharma with real-world
data insights.
In recognition of our endeavour to pursue a long-term
perspective in all we do, Roche has been named one of the most
sustainable companies in the pharmaceuticals industry by the Dow
Jones Sustainability Indices for the fifteenth consecutive year.
This distinction also reflects our efforts to improve access to
healthcare together with local partners.
Genentech in the United States is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
Roche Group Media Relations
Phone: +41 61 688 888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58
|
Nathalie
Altermatt
Phone: +41 79 771 05 25
|
Simon
Goldsborough
Phone: +44 797 32 72 915 |
Karsten
Kleine
Phone: +41 79 461 86 83
|
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262
|
Dr
Rebekka Schnell
Phone: +41 79 205 27 03 |
Sileia
Urech
Phone: +41 79 935 81 48 |
- 12032024_MR_RocheAGM_EN (1)
Roche (LSE:0QQ6)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Roche (LSE:0QQ6)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024